ClinicalTrials.gg
Not yet recruitingNCT07951606Updated Nov 20, 2026

Safty and Efficacy of KH658 in Subjects With Diabetic Retinopathy

A Phase 2 interventional study of KH658 Dose 1 and KH658 Dose 2 in Diabetic Retinopathy, sponsored by Chengdu Origen Biotechnology Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Chengdu Origen Biotechnology Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 85 studies in Diabetic Retinopathy with a site in China — 27 open to participants now, 28 under way, 2 of them phase 3. Diabetic Retinopathy · China.

Planned enrollment
49th of 56
48 · median 139
Started
2027
the only one that year
Phase 2
6 of 85
2 open now
Primary completion
2028-06
later than 23 of 27 live
Registered
85th of 85
by date

Among the 85 studies in Diabetic Retinopathy with a site in China, this one is the 49th largest by planned enrollment of the 56 interventional ones that give a count, is the only one that started in 2027, is one of 6 in phase 2, reaches primary completion later than 23 of the 27 other live ones, and was the 85th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

27 of the 85 studies in Diabetic Retinopathy with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Diabetic Retinopathy with a site in China, or all of them as a file.
02

Study summary

KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for DR could potentially reduce the treatment burden and maintain visual acuity and retinal anatomical stability

03

Conditions studied

  • Diabetic Retinopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are willing and able to sign the form (ICF);
  2. Male or female ≥ 18 to 85 years of age with DR secondary to diabetes mellitus Type 1 or Type 2;
  3. Moderately Severe NPDR or Severe NPDR (DRSS levels 47-53);
  4. Have a ETDRS BCVA letter score of ≥ 69 (approximately 20/40 Snellen equivalent) in the study eye at Screening;
  5. Have a ETDRS BCVA letter score of ≥19 (approximately 20/400 Snellen equivalent) in the fellow eye at Screening;
  6. No active CI-DME

Exclusion criteria

Exclusion Criteria:

  1. Have any non-DR disease in the study eye judged by the investigator that could impact macular examination or affect central vision or visual acuity improvement (such as macular hemorrhage, central retinal vein occlusion, fovea scar, fibrosis or atrophy etc.);
  2. Have any vitreous hemorrhage or history of vitreous hemorrhage in the study eye;
  3. Presence of an implant (excluding intraocular lens), opacification of the refractive medium or miosis that affects fundus examination;
  4. Have a history of or presence of retinal detachment or choroidal detachment in the study eye.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    KH658 Dose 1

    In-office delivers KH658 to the suprachoroidal space

    Genetic: KH658 Dose 1

  • Experimental
    KH658 Dose 2

    In-office delivers KH658 to the suprachoroidal space

    Genetic: KH658 Dose 2

  • Active comparator
    Ranibizumab

    Ranibizumab IVT Injection

    Drug: Ranibizumab

  • No intervention
    Observational Control

    Observational Control

Interventions

  • GeneticKH658 Dose 1

    KH658 Dose 1 suprachoriodal single injection

  • GeneticKH658 Dose 2

    KH658 Dose 2 suprachoriodal single injection

  • Administered by intravitreal injection once a month

06

What researchers measure

Primary outcomes

  1. Proportion of Participants with a ≥2 steps DRSS Improvement From Baseline in Diabetic Retinopthy

    To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants achieving a ≥2 steps improvement on the DRSS from baseline.

    Time frame: At Week 52

  2. Proportion of Participants Developing Vision-Threatening Events (VTEs)

    To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants developing VTEs. VTEs include vision-threatening complications (VTCs) and center-involved diabetic macular edema (CI-DME) requiring rescue treatment.

    Time frame: At Week 52

Secondary outcomes

  1. Proportion of Participants With Improvement, Maintanance, or Worsening in DRSS Score From Baseline

    To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants demonstrating improvement, maintance, or worsening in the DRSS score compared to baseline.

    Time frame: At Week 24, Week 52

  2. Time to first occurrence of VTEs

    To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the time to first occurrence of VTEs.

    Time frame: Day 1 to Week 52

  3. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    To evaluate the safty of KH658 ophthalmic injection in patients with DR, assessed by the incidence of AEs and SAEs

    Time frame: Through Week 52

Other outcomes

  1. Number of rescue treatments

    To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the number of rescue treatments

    Time frame: At Week 24, Week 52

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Jun 2028, 16 months later.

Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's planned 16 months is below that.

Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Feb 2027
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2032
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951606
Lead sponsor
Chengdu Origen Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Feb 2027 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jun 2032 (estimated)
Last update
Nov 20, 2026

Study contacts

Yan Cheng
Contact
025171@cnkh.com
86-028-81258178

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion